Episode Details
Back to Episodes
Episode 74 - Roy Maute - CEO of Pheast Therapeutics
Published 1 year ago
Description
On this episode we had the pleasure of featuring Roy Maute of Pheast Therapeutics.
Pheast are unleashing the power of macrophages in oncology, starting in advanced solid tumours & Ovarian Cancer. Their pipeline consists of novel innate immune checkpoint inhibitors (incl. Anti-CD24), based on research out of Irv Weissman's lab at Stanford.
In this episode we cover the inspiration behind Roy's career in oncology R&D & the origins of Pheast's name & platform, before moving onto Pheast's recent (FTD, ph1 entry) and upcoming milestones. We also cover their big ambitions for the future & how their huge focus on culture as a business has & continues to shape their journey.